التفاصيل البيبلوغرافية
| العنوان: |
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) |
| المؤلفون: |
James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater |
| المصدر: |
Respiratory Research, Vol 20, Iss 1, Pp 1-10 (2019) |
| بيانات النشر: |
BMC, 2019. |
| سنة النشر: |
2019 |
| المجموعة: |
LCC:Diseases of the respiratory system |
| مصطلحات موضوعية: |
Diseases of the respiratory system, RC705-779 |
| الوصف: |
Abstract Background Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenacin in COPD, longer-term efficacy has not been described. In a recent 52-week safety trial, revefenacin was well tolerated and had a favorable benefit-risk profile. Here we report exploratory efficacy and health outcomes in patients receiving revefenacin 175 μg or 88 μg daily during the 52-week trial. Methods In this randomized, parallel-group, 52-week trial (NCT02518139), 1055 participants with moderate to very severe COPD received revefenacin 175 μg or 88 μg in a double-blind manner, or open-label active control tiotropium. Results Over the 52-week treatment period, both doses of revefenacin, as well as tiotropium, elicited significant (all p |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1465-993X |
| Relation: |
http://link.springer.com/article/10.1186/s12931-019-1187-7; https://doaj.org/toc/1465-993X |
| DOI: |
10.1186/s12931-019-1187-7 |
| URL الوصول: |
https://doaj.org/article/198bfe3495a340e7a38a0033b3384475 |
| رقم الانضمام: |
edsdoj.198bfe3495a340e7a38a0033b3384475 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder